© 2020 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Chronic Lymphocytic Leukemia
Barr Evaluates BTK Inhibitors for Treating Frontline CLL
August 29, 2020
During a virtual Case Based Peer Perspectives event, Paul M. Barr, MD, reviewed the case of a 71-year-old woman with newly diagnosed chronic lymphocytic leukemia and the role of BTK inhibitors in the frontline setting.
Portell Discusses the Treatment of Relapsed/Refractory CLL
August 27, 2020
During a virtual Case Based Peer Perspectives event, Craig A. Portell, MD, discussed how he would go about treating a patient case with chronic lymphocytic leukemia.
Burger Reviews BTK Inhibitors and Beyond in Frontline CLL
August 25, 2020
During a virtual Case Based Peer Perspectives event, Jan A. Burger, MD, PhD, discussed testing and the treatment options for chronic lymphocytic leukemia, based on a case of 71-year-old female patient.
Obinutuzumab Triplet Achieves Deep Remissions in Chronic Lymphocytic Leukemia
August 20, 2020
“The regimen of obinutuzumab, ibrutinib, and venetoclax met its primary goal of achieving deep remissions with a fixed-duration combination of targeted agents.”
Expert Highlights Role of BTK Inhibition in Treatment Landscape for CLL
August 18, 2020
In an interview with Targeted Oncology, Jennifer Woyach, MD, discussed the current treatment landscape for patients with chronic lymphocytic leukemia and some of the latest research regarding the BTK inhibitors.
COVID-19 Severity in CLL Correlates With 3 Disease Characteristics
August 18, 2020
The severity of coronavirus disease 2019 increases with age in patients with chronic lymphocytic leukemia. However, age and the existence of comorbidities may not impact death from COVID-19, according to results from a retrospective international study.
Ibrutinib May Improve CAR T-Cell Production for Patients With Chronic Lymphocytic Leukemia
August 17, 2020
Ibrutinib during CAR T-cell culture improved the yield and function of CAR T-cell products as treatment of patients with chronic lymphocytic leukemia.
Ibrutinib Plus Umbralisib Induce Survival Benefit in Patients With CLL
August 17, 2020
Matthew Davids, MD, MMSc, discusses the longer-term follow-up data from the phase 3 UNITY-CLL clinical trial, which evaluated umbralisib in combination with ibrutinib as treatment of patients with chronic lymphocytic leukemia.
Coutre Evaluates Treatment Options in Relapsed/Refractory CLL
August 13, 2020
During a virtual Case Based Peer Perspectives event, Steven Coutre, MD, reviewed a case of a 53-year-old woman who first presented with elevated white blood cell count. The patient was later diagnosed with chronic lymphocytic leukemia.
Cohen Expands on Treatment Options in Patients With Genomic Aberrations in CLL
August 12, 2020
During a virtual Case Based Peer Perspective event, Jonathon B. Cohen, MD, MS, discussed a case of a 71-year-old woman diagnosed with chronic lymphocytic leukemia.